AI Revolutionizes Drug Discovery: Lilly’s $2.75 Billion Bet on Insilico The pharmaceutical industry is undergoing a seismic shift, driven by the rapid advancements in artificial intelligence. This week, Eli Lilly took a massive leap forward, announcing a $2.75 billion deal with Hong Kong-based Insilico Medicine to accelerate the development of AI-discovered drugs. This collaboration isn’t … Read more
CNBC Cures: A Turning Tide for Rare Disease Awareness and Innovation The launch of CNBC Cures, spearheaded by Becky Quick and her sister, marks a significant shift in how rare diseases are discussed and addressed. What began as a personal mission – driven by Quick’s own family’s experience with a rare disease diagnosis – has … Read more
Lilly’s New Playbook: Expanding Access to Obesity Drugs and Reshaping the Market Eli Lilly has launched “Employer Connect,” a new platform aimed at making its obesity drug, Zepbound, more accessible to employees through their health insurance. This move addresses a significant hurdle in the rapidly evolving obesity treatment landscape: cost and inconsistent employer coverage. Although … Read more
Novo Nordisk’s Setback: What the CagriSema Trial Means for the Future of Obesity Drugs Novo Nordisk’s stock experienced a significant 15% drop on Monday after announcing its next-generation weight loss drug, CagriSema, did not demonstrate superiority to Eli Lilly’s tirzepatide in a recent trial. This news arrives as Eli Lilly’s drugs, Mounjaro and Zepbound, are … Read more
Hims & Hers’ $1.15 Billion Bet on Eucalyptus: A Sign of Telehealth’s Global Expansion? Hims & Hers Health’s agreement to acquire Australian digital health company Eucalyptus for up to $1.15 billion signals a significant shift in the telehealth landscape. This move isn’t just about expanding into new markets. it’s a strategic play for a future … Read more
Hims & Hers Retreats from Wegovy Copycat: What It Means for the Future of Weight-Loss Drugs Novo Nordisk shares surged Monday after Hims & Hers announced it would discontinue sales of its cheaper, compounded version of the weight-loss pill Wegovy. The move comes after threats of legal action from Novo Nordisk and scrutiny from the … Read more
Pfizer’s Pivot: Navigating a Post-COVID World and the Future of Pharma Pfizer’s recent fourth-quarter earnings report, while exceeding Wall Street expectations, paints a clear picture: the era of blockbuster COVID-19 revenue is waning. The company is now aggressively shifting its focus, and its future hinges on strategic acquisitions, cost-cutting measures, and navigating a complex landscape … Read more
The Obesity Drug Revolution: How Medicare Coverage and Trump’s Plan Could Reshape the Market The landscape of obesity treatment is poised for a dramatic shift. Eli Lilly CEO Dave Ricks recently signaled that upcoming Medicare coverage, coupled with pricing agreements struck with the Trump administration, could be a game-changer for the rollout of their experimental … Read more
President Donald Trump announced Monday a new round of tariffs on goods imported from South Korea, increasing duties on autos, pharmaceuticals, and lumber from 15% to 25%. The action comes in response to a delay in the South Korean legislature’s approval of a trade deal initially reached with the United States last summer. Tariff Increase … Read more
The Shifting Sands of Pharma: Navigating Patent Cliffs, Deals, and a New Political Landscape The pharmaceutical industry entered 2026 with a cautious optimism, a sentiment echoing from the recent JPMorgan Healthcare Conference in San Francisco. While geopolitical uncertainties lingered in 2025, a potential turning point for the sector is on the horizon, fueled by falling … Read more